Reference
Govers T, et al. Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment. Journal of Urology : 15 Jul 2018. Available from: URL: http://doi.org/10.1016/j.juro.2018.07.034
Rights and permissions
About this article
Cite this article
SelectMDx optimises value of prostate cancer risk assessment. PharmacoEcon Outcomes News 809, 35 (2018). https://doi.org/10.1007/s40274-018-5187-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5187-5